The @entity876 Arg72Pro polymorphism, @entity1082 , and invasive XXXX .

@entity1 @entity5 @entity534 @entity876 @entity1544 @entity1799 @entity1082 @entity3 @entity1521 @entity369
A. Storey et al. [Nature (Lond.), 393: 229-234, 1998)] reported a 7-fold increased risk of @entity5 associated with having an @entity534 / @entity534 polymorphism at codon 72 of @entity876 compared with the Pro/ @entity534 heterozygotes (odds ratio, 7.4; 95% confidence interval, 2.1-29.4). Complementary in vitro studies suggested that the HPV E6 oncoprotein more readily targets the @entity369 form, as opposed to the @entity1521 form, of @entity876 for degradation. We investigated the impact of this polymorphism in a population-based case-control study of @entity3 . Using a PCR assay to detect the @entity876 codon 72 polymorphism, we tested blood samples from 111 @entity1 with invasive @entity1544 of the cervix identified by a population-based registry and 164 random-digit telephone-dialed controls. The distribution of the genotype among control @entity1 was 38% heterozygous, 7% @entity1521 homozygous, and 55% @entity369 homozygous, and among the cases was 38%, 6%, and 56%, respectively. There was no increased risk of @entity1544 associated with homozygosity for the @entity369 allele (odds ratio, 1.0; 95% confidence interval, 0.6-1.7). Furthermore, there was no modification of this result by @entity1082 ) DNA status of the @entity5 , age, or smoking status. Among controls, there was no association between the polymorphism and @entity1799 L1 seropositivity. However, among case subjects, the codon 72 polymorphism may be related to @entity1799 L1 seropositivity status.
